Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy

An inactivating PHEX gene mutation with the resultant accumulation of several mineralization-inhibiting proteins (e.g., FGF23) causes skeletal and dental morbidity in X-linked hypophosphatemia (XLH). This prospective case-control study explored the effect of burosumab, an anti-FGF23 antibody, on den...

Descripción completa

Detalles Bibliográficos
Autores principales: Brener, Rafi, Zeitlin, Leonid, Lebenthal, Yael, Brener, Avivit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425915/
https://www.ncbi.nlm.nih.gov/pubmed/36051396
http://dx.doi.org/10.3389/fendo.2022.947814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425915/
https://www.ncbi.nlm.nih.gov/pubmed/36051396
http://dx.doi.org/10.3389/fendo.2022.947814

Ejemplares similares